Vol 54, No 1 (2020)
Research Paper
Published online: 2020-01-17

open access

Page views 2070
Article views/downloads 1646
Get Citation

Connect on Social Media

Connect on Social Media

Differences in the courses of meningococcal and pneumococcal cerebrospinal meningitis

Wojciech Szymański1, Krzysztof Simon1, Marta Rorat1
Pubmed: 31956973
Neurol Neurochir Pol 2020;54(1):39-46.

Abstract

Neisseria meningitidis and Streptococcus pneumoniae are the most common pathogens causing cerebrospinal meningitis (CSM) in adults. The mortality rate and the number of complications remain high. In our study, retrospective evaluations were conducted on data concerning 98 adult patients with bacterial cerebrospinal meningitis caused by Neisseria meningitidis (n = 42) and Streptococcus pneumoniae (n = 56), hospitalised at the Regional Specialistic Hospital in Wroclaw (Poland) within the period 1998–2018.
Compared to the group infected with S. pneumoniae, patients infected with N. meningitidis were younger and were less often affected by an additional disease burden; they presented more frequently with haemorrhagic rashes. Compared to the S. pneumoniae group, in patients with meningococcal CSM, cytosis in cerebrospinal fluid measuring < 1,000 cells/ mL was less frequent; intravascular coagulation syndrome appeared more frequently; the hospitalisation time was shorter and the rate of mortality was lower. Meningococcal meningitis occurs more frequently among young people with no history of disease. It is characterised by the rapid development of symptoms, which results in earlier diagnosis and more favourable prognosis compared to cases of S. pneumoniae. Irrespective of the pathogen, advanced age and a level of cytosis in cerebrospinal fluid of < 1,000 cells /μl indicate an unfavourable prognosis.

Article available in PDF format

View PDF Download PDF file

References

  1. Paradowska-Stankiewicz I, Piotrowska A. Meningitis and encephalitis in Poland in 2015. Przegl Epidemiol. 2017; 71(4): 493–500.
  2. Paradowska-Stankiewicz I, Piotrowska A. Meningitis and encephalitis in Poland in 2014. Przegl Epidemiol. 2016; 70(3): 349–357.
  3. Bacterial Infections of the Central Nervous System. Handbook of Clinical Neurology. 2010.
  4. Department for Communicable Disease and Infection Prevention and Control. Infectious diseases and poisonings in Poland in 2016. 2017.
  5. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004; 351(18): 1849–1859.
  6. Adriani KS, Brouwer MC, van de Beek D, et al. Community-acquired recurrent bacterial meningitis in adults. Clin Infect Dis. 2007; 45(5): e46–e51.
  7. Mace SE. Acute bacterial meningitis. Emerg Med Clin North Am. 2008; 26(2): 281–317, viii.
  8. Brouwer MC. Bacterial meningitis in adults: clinical characteristics, risk factors and adjunctive treatment. University of Amsterdam. 2010.
  9. Berg S, Trollfors B, Claesson BA, et al. Incidence and prognosis of meningitis due to Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis in Sweden. Scand J Infect Dis. 1996; 28(3): 247–252.
  10. Lucas MJ, Brouwer MC, van de Beek D, et al. Endocarditis in adults with bacterial meningitis. Circulation. 2013; 127(20): 2056–2062.
  11. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004; 351(18): 1849–1859.
  12. Bijlsma M, Brouwer M, Kasanmoentalib E, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. The Lancet Infectious Diseases. 2016; 16(3): 339–347.
  13. Schut ES, Lucas MJ, Brouwer MC, et al. Cerebral infarction in adults with bacterial meningitis. Neurocrit Care. 2012; 16(3): 421–427.
  14. Santos LC, Simões J, Severo M, et al. Bacterial meningitis in an urban area: etiologic study and prognostic factors. Infection. 2007; 35(6): 406–413.
  15. Proulx N, Fréchette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM. 2005; 98(4): 291–298.
  16. Kepa L, Wilczek K, Karasińska M. [Meningitis and encephalitis in the years 1983-1990. Clinical observations]. Przegl Epidemiol. 1991; 45(3): 183–189.
  17. Wrodycki W, Kuydowicz J, Krakowiak M, et al. [Epidemiologic-clinical analysis of purulent meningitis in adults: material from the Clinic of Infectious Diseases AM in Lodz in the years 1990-1991]. Pol Tyg Lek. 1994; 49(20-22): 462–464.
  18. Kuchar E, Nitsch-Osuch A, Rorat M, et al. Etiology and complications of central nervous system infections in children treated in a pediatric intensive care unit in Poland. J Child Neurol. 2014; 29(4): 483–486.
  19. R Core Team. R: A language and environment for statistical computing 2018.
  20. Lodder MC, Schildkamp RL, Bijlmer HA, et al. Prognostic indicators of the outcome of meningococcal disease: a study of 562 patients. J Med Microbiol. 1996; 45(1): 16–20.
  21. Bijlsma M, Brouwer M, Kasanmoentalib E, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. The Lancet Infectious Diseases. 2016; 16(3): 339–347.
  22. Stephens D, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The Lancet. 2007; 369(9580): 2196–2210.
  23. Stanek RJ, Mufson MA. A 20-year epidemiological study of pneumococcal meningitis. Clin Infect Dis. 1999; 28(6): 1265–1272.
  24. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000; 13(1): 144–66, table of contents.
  25. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010; 50(2): 184–191.
  26. Weisfelt M, van de Beek D, Spanjaard L, et al. Attenuated cerebrospinal fluid leukocyte count and sepsis in adults with pneumococcal meningitis: a prospective cohort study. BMC Infect Dis. 2006; 6: 149.
  27. Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system. Curr Opin Immunol. 2005; 17(5): 457–462.
  28. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis. 2010; 50(3): 329–337.
  29. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006; 367(9508): 397–403.
  30. Hussein AS, Shafran SD. Acute bacterial meningitis in adults. A 12-year review. Medicine (Baltimore). 2000; 79(6): 360–368.
  31. Pfeffer M, Braunwald E, Moyé L, et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction [do weryfikacji!!!]. New England Journal of Medicine. 1992; 327(10): 669–677.
  32. Brandtzaeg P, Dahle JS, Høiby EA. The occurrence and features of hemorrhagic skin lesions in 115 cases of systemic meningococcal disease. NIPH Ann. 1983; 6(2): 183–90, 202.
  33. Andreasen TJ, Green SD, Childers BJ. Massive infectious soft-tissue injury: diagnosis and management of necrotizing fasciitis and purpura fulminans. Plast Reconstr Surg. 2001; 107(4): 1025–1035.
  34. Alvarez EF, Olarte KE, Ramesh MS. Purpura Fulminans Secondary to Streptococcus pneumoniae Meningitis. Case Rep Infect Dis. 2012; 2012: 508503.
  35. van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis in adults. N Engl J Med. 2006; 354(1): 44–53.
  36. Lagi F, Bartalesi F, Pecile P, et al. Proposal for a New Score-Based Approach To Improve Efficiency of Diagnostic Laboratory Workflow for Acute Bacterial Meningitis in Adults. J Clin Microbiol. 2016; 54(7): 1851–1854.
  37. Lynch JP. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest. 2001; 119(2 Suppl): 373S–384S.
  38. Taylor F, Toh CH, Hoots K, et al. Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation. Thrombosis and Haemostasis. 2017; 86(11): 1327–1330.
  39. Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child. 2003; 88(7): 601–607.
  40. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005; 128(4): 2864–2875.
  41. Brandtzaeg P, Joø GB, Brusletto B, et al. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res. 1990; 57(2): 271–278.
  42. Heckenberg S. Bacterial meningitis in adults: host and pathogen factors, treatment and outcome. Universiteit van Amsterdam. 2013.
  43. Østergaard C, Konradsen HB, Samuelsson S. Clinical presentation and prognostic factors of Streptococcus pneumoniae meningitis according to the focus of infection. BMC Infect Dis. 2005; 5: 93.
  44. Weisfelt M, van de Beek D, Spanjaard L, et al. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol. 2006; 5(2): 123–129.
  45. Brouwer MC, McIntyre P, Prasad K, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015(9): CD004405.